EARNINGS PER SHARE

12 Months Ended

Dec. 31, 2024

NOTE 8 – EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations.

Basic earnings (loss) per share are computed by dividing net earnings available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period:

	2024		2023
	For the Years Ended December 31,
	2024		2023
Options to purchase shares of common stock		120,000		120,000
Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.*		400,000		400,000
Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol*		300,000		300,000
Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc.		400,000		400,000
Warrants to purchase shares of common stock		490,000		490,000
Total potentially dilutive shares		1,710,000		1,710,000

*	The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.

The following table sets forth the computation of basic and diluted net income per share:

	2024			2023
	For the Years Ended December 31,
	2024			2023
Net loss attributable to the common stockholders	$	(100,484	)	$	(805,021	)

Basic weighted average outstanding shares of common stock		20,262,354			8,475,950
Dilutive effect of options and warrants		-			-
Diluted weighted average common stock and common stock equivalents		20,262,354			8,475,950

Loss per share:
Basic and diluted	$	(0.00	)	$	(0.09	)

FAMILY OFFICE OF AMERICA, INC. 10-K